Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines

Gordon H. Guyatt, John W. Eikelboom, Michael K. Gould, David A. Garcia, Mark Crowther, Mohammad H Murad, Susan R. Kahn, Yngve Falck-Ytter, Charles W. Francis, Maarten G. Lansberg, Elie A. Akl, Jack Hirsh

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

This article provides the rationale for the approach to making recommendations primarily used in four articles of the Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines: orthopedic surgery, nonorthopedic surgery, nonsurgical patients, and stroke. Some of the early clinical trials of antithrombotic prophylaxis with a placebo or no treatment group used symptomatic VTE and fatal PE to measure efficacy of the treatment. These trials suggest a benefit of thromboprophylaxis in reducing fatal PE. In contrast, most of the recent clinical trials comparing the efficacy of alternative anticoagulants used a surrogate outcome, asymptomatic DVT detected at mandatory venography. This outcome is fundamentally unsatisfactory because it does not allow a trade-off with serious bleeding; that trade-off requires knowledge of the number of symptomatic events that thromboprophylaxis prevents. In this article, we review the merits and limitations of four approaches to estimating reduction in symptomatic thrombosis: (1) direct measurement of symptomatic thrombosis, (2) use of asymptomatic events for relative risks and symptomatic events from randomized controlled trials for baseline risk, (3) use of baseline risk estimates from studies that did not perform surveillance and relative effect from asymptomatic events in randomized controlled trials, and (4) use of available data to estimate the proportion of asymptomatic events that will become symptomatic. All approaches have their limitations. The optimal choice of approach depends on the nature of the evidence available.

Original languageEnglish (US)
JournalChest
Volume141
Issue number2 SUPPL.
DOIs
StatePublished - Feb 2012

Fingerprint

Evidence-Based Practice
Practice Guidelines
Thrombosis
Randomized Controlled Trials
Clinical Trials
Phlebography
Anticoagulants
Orthopedics
Therapeutics
Stroke
Placebos
Hemorrhage

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients. Antithrombotic therapy and prevention of thrombosis, 9th ed : American College of Chest Physicians evidence-based clinical practice guidelines. / Guyatt, Gordon H.; Eikelboom, John W.; Gould, Michael K.; Garcia, David A.; Crowther, Mark; Murad, Mohammad H; Kahn, Susan R.; Falck-Ytter, Yngve; Francis, Charles W.; Lansberg, Maarten G.; Akl, Elie A.; Hirsh, Jack.

In: Chest, Vol. 141, No. 2 SUPPL., 02.2012.

Research output: Contribution to journalArticle

Guyatt, Gordon H. ; Eikelboom, John W. ; Gould, Michael K. ; Garcia, David A. ; Crowther, Mark ; Murad, Mohammad H ; Kahn, Susan R. ; Falck-Ytter, Yngve ; Francis, Charles W. ; Lansberg, Maarten G. ; Akl, Elie A. ; Hirsh, Jack. / Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients. Antithrombotic therapy and prevention of thrombosis, 9th ed : American College of Chest Physicians evidence-based clinical practice guidelines. In: Chest. 2012 ; Vol. 141, No. 2 SUPPL.
@article{69d84be346854cc3b56abfc8ca145182,
title = "Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines",
abstract = "This article provides the rationale for the approach to making recommendations primarily used in four articles of the Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines: orthopedic surgery, nonorthopedic surgery, nonsurgical patients, and stroke. Some of the early clinical trials of antithrombotic prophylaxis with a placebo or no treatment group used symptomatic VTE and fatal PE to measure efficacy of the treatment. These trials suggest a benefit of thromboprophylaxis in reducing fatal PE. In contrast, most of the recent clinical trials comparing the efficacy of alternative anticoagulants used a surrogate outcome, asymptomatic DVT detected at mandatory venography. This outcome is fundamentally unsatisfactory because it does not allow a trade-off with serious bleeding; that trade-off requires knowledge of the number of symptomatic events that thromboprophylaxis prevents. In this article, we review the merits and limitations of four approaches to estimating reduction in symptomatic thrombosis: (1) direct measurement of symptomatic thrombosis, (2) use of asymptomatic events for relative risks and symptomatic events from randomized controlled trials for baseline risk, (3) use of baseline risk estimates from studies that did not perform surveillance and relative effect from asymptomatic events in randomized controlled trials, and (4) use of available data to estimate the proportion of asymptomatic events that will become symptomatic. All approaches have their limitations. The optimal choice of approach depends on the nature of the evidence available.",
author = "Guyatt, {Gordon H.} and Eikelboom, {John W.} and Gould, {Michael K.} and Garcia, {David A.} and Mark Crowther and Murad, {Mohammad H} and Kahn, {Susan R.} and Yngve Falck-Ytter and Francis, {Charles W.} and Lansberg, {Maarten G.} and Akl, {Elie A.} and Jack Hirsh",
year = "2012",
month = "2",
doi = "10.1378/chest.11-2289",
language = "English (US)",
volume = "141",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "2 SUPPL.",

}

TY - JOUR

T1 - Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients. Antithrombotic therapy and prevention of thrombosis, 9th ed

T2 - American College of Chest Physicians evidence-based clinical practice guidelines

AU - Guyatt, Gordon H.

AU - Eikelboom, John W.

AU - Gould, Michael K.

AU - Garcia, David A.

AU - Crowther, Mark

AU - Murad, Mohammad H

AU - Kahn, Susan R.

AU - Falck-Ytter, Yngve

AU - Francis, Charles W.

AU - Lansberg, Maarten G.

AU - Akl, Elie A.

AU - Hirsh, Jack

PY - 2012/2

Y1 - 2012/2

N2 - This article provides the rationale for the approach to making recommendations primarily used in four articles of the Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines: orthopedic surgery, nonorthopedic surgery, nonsurgical patients, and stroke. Some of the early clinical trials of antithrombotic prophylaxis with a placebo or no treatment group used symptomatic VTE and fatal PE to measure efficacy of the treatment. These trials suggest a benefit of thromboprophylaxis in reducing fatal PE. In contrast, most of the recent clinical trials comparing the efficacy of alternative anticoagulants used a surrogate outcome, asymptomatic DVT detected at mandatory venography. This outcome is fundamentally unsatisfactory because it does not allow a trade-off with serious bleeding; that trade-off requires knowledge of the number of symptomatic events that thromboprophylaxis prevents. In this article, we review the merits and limitations of four approaches to estimating reduction in symptomatic thrombosis: (1) direct measurement of symptomatic thrombosis, (2) use of asymptomatic events for relative risks and symptomatic events from randomized controlled trials for baseline risk, (3) use of baseline risk estimates from studies that did not perform surveillance and relative effect from asymptomatic events in randomized controlled trials, and (4) use of available data to estimate the proportion of asymptomatic events that will become symptomatic. All approaches have their limitations. The optimal choice of approach depends on the nature of the evidence available.

AB - This article provides the rationale for the approach to making recommendations primarily used in four articles of the Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines: orthopedic surgery, nonorthopedic surgery, nonsurgical patients, and stroke. Some of the early clinical trials of antithrombotic prophylaxis with a placebo or no treatment group used symptomatic VTE and fatal PE to measure efficacy of the treatment. These trials suggest a benefit of thromboprophylaxis in reducing fatal PE. In contrast, most of the recent clinical trials comparing the efficacy of alternative anticoagulants used a surrogate outcome, asymptomatic DVT detected at mandatory venography. This outcome is fundamentally unsatisfactory because it does not allow a trade-off with serious bleeding; that trade-off requires knowledge of the number of symptomatic events that thromboprophylaxis prevents. In this article, we review the merits and limitations of four approaches to estimating reduction in symptomatic thrombosis: (1) direct measurement of symptomatic thrombosis, (2) use of asymptomatic events for relative risks and symptomatic events from randomized controlled trials for baseline risk, (3) use of baseline risk estimates from studies that did not perform surveillance and relative effect from asymptomatic events in randomized controlled trials, and (4) use of available data to estimate the proportion of asymptomatic events that will become symptomatic. All approaches have their limitations. The optimal choice of approach depends on the nature of the evidence available.

UR - http://www.scopus.com/inward/record.url?scp=84856791099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856791099&partnerID=8YFLogxK

U2 - 10.1378/chest.11-2289

DO - 10.1378/chest.11-2289

M3 - Article

C2 - 22315260

AN - SCOPUS:84856791099

VL - 141

JO - Chest

JF - Chest

SN - 0012-3692

IS - 2 SUPPL.

ER -